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Background: Lymph node (LN) status is a major determinant of
stage and survival in patients with lung cancer. In the 7th edition of
the TNM Classification of Malignant Tumors, the number of in-
volved LNs is included in the definition of pN factors in breast,
stomach, esophageal, and colorectal cancer, and the pN status
significantly correlates with prognosis.
Methods:We retrospectively investigated the prognostic impact of the
number of resected LNs (RLNs) and involved LNs in the context of
other established clinical prognostic factors, in a series of 928 consec-
utive patients with non-small cell lung cancer (NSCLC) who underwent
complete resection at our institution between 2000 and 2007.
Results: The mean number of RLNs was 15. There was a significant
difference in the total number of RLNs categorized between less
than 10 and 10 (p  0.0129). Although the incidence of LN
involvement was statistically associated with poor prognosis, the
largest statistically significant increase in overall survival was ob-
served between 0 to 3 and 4 involved LNs (hazard ratio  7.680;
95% confidence interval  5.051–11.655, p  0.0001). On multi-
variate analysis, we used the ratio between the number of involved
LNs and RLNs. The number of RLNs was found to be a strong
independent prognostic factor for NSCLC (hazard ratio  6.803;
95% confidence interval  4.137–11.186, p  0.0001).
Conclusion: Complete resection including 10 or more LNs influ-
enced survival at complete NSCLC resection. Four involved LNs
seemed to be a benchmark for NSCLC prognosis. The number of
involved LNs is a strong independent prognostic factor in NSCLC,
and the results of this study may provide new information for
determining the N category in the next tumor, node, metastasis
classification.
Key Words: Number of resected lymph nodes, Number of involved
lymph nodes, Lymph node dissection, Multivariate analysis.
(J Thorac Oncol. 2011;6: 1865–1871)
Lung cancer has one of the highest worldwide incidencerates and is the leading cause of cancer-related mortality
worldwide.1 In Japan, lung cancer accounts for 60,000 deaths
annually, and surgical resections are performed in approxi-
mately 27,000 cases, with an overall survival (OS) rate of
60%, according to the annual reports of the Japanese Asso-
ciation for Thoracic Surgery2 and the Japanese Lung Cancer
Registry.3
Various pathological and molecular markers have been
assessed regarding their status and role in identifying patients
at high risk for recurrence. However, the primary tumor,
lymph node (LN), and the metastasis (TNM) staging system
remain the most important determinant of outcome. Because
the prognosis of lung cancer is directly proportional to the
presence of LN metastasis, accurate LN assessment is crucial
in determining treatment. The role of hilar and mediastinal
lymphadenectomy in the staging and treatment of non-small
cell lung cancer (NSCLC) remains controversial. Accurate
staging of NSCLC requires assessment of the hilar and
mediastinal LNs based on pathologic evaluation. In almost all
surgical cooperative group trials and clinical settings in Ja-
pan, systematic LN dissection in ipsilateral hilar and medi-
astinal stations is standard. However, there is continual de-
bate regarding the degree to which hilar and mediastinal LNs
should be located and removed.
The number of resected LNs (RLNs) has been proven
to have prognostic value in colorectal, breast, and bladder
cancer.4–6 Moreover, the number of involved LNs at the time
of surgery currently influences staging. However, these items
have not yet been incorporated into the latest 7th edition of
the TNM classification of lung cancer.7
Therefore, we retrospectively investigated the prognostic
impact of the number of RLNs and involved LNs in the context
of other established clinical prognostic factors, in a series of 928
consecutive patients with NSCLC who underwent complete
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resection at Tokyo Medical University. Specifically, we at-
tempted to clarify the number of LNs that should be resected,
and the number of involved LNs needed to make an accurate
prognosis.
PATIENTS AND METHODS
Patient Selection
From January 2000 to November 2007, a total of 1311
patients underwent resection for primary lung cancer at our
institution. Cases of induction therapy, incomplete resection,
and limited resection were excluded from this study. Patients
whose tumors were classified histologically as small cell lung
cancer or low-grade malignant tumors were also excluded.
We retrospectively analyzed the remaining 928 consecutive
patients with NSCLC who underwent complete resection
with curative intent (minimum procedure of lobectomy) with
systematic LN dissection of the hilum and mediastinum
according to current surgical methods.8 Patient charts, includ-
ing pathologic diagnosis and operative reports, were re-
viewed. Staging was determined according to the interna-
tional TNM staging system.9 The histological tumor type was
determined according to the World Health Organization clas-
sification, 3rd edition. All dissected LNs were examined
pathologically and classified according to anatomical location
by the numbering system described in the Naruke map.10 The
number of RLNs and involved LNs was confirmed based on
the pathological report provided by M.N., J.M., and T.N.
These pathologists were blinded to the clinical outcome.
Patient Characteristics
The characteristics of the 928 consecutive patients who
underwent surgery for NSCLC were as follows: age, median
(range): 65.0 years (22–87 years); sex: 547 (59.0%) men and
381 (41.0%) women; clinical stages: 768 (82.8%) stage I, 84
(9.1%) stage II, and 76 (8.1%) stage III; pathological stage:
677 (72.9%) stage I, 121 (13.0%) stage II, 129 (13.9%) stage
III, and 1 (0.2%) stage IV; histopathological diagnosis: 684
(73.7%) adenocarcinomas, 182 (19.6%) squamous cell carci-
nomas, 52 (5.6%) large cell carcinomas, and 10 (1.1%)
others; surgical procedure: 870 (93.8%) lobectomies, 42
(4.5%) bilobectomies, and 16 (1.7) pneumonectomies. The
mean number of RLNs was 15 (right side, 15.5; left side,
14.3); the mean number of involved LNs was 4.2 (0–22)
(Table 1). The median follow-up time was 3.5 years.
Statistical Analysis
We investigated the association between the total num-
ber of RLNs or involved LNs and OS. OS was calculated
from the date of surgery to the time of death. Observations
were censored at final follow-up if the patient was alive. All
patients in this series were categorized into four groups
according to the number of RLNs less than 5 versus 5 or
more, less than 10 versus 10 or more, less than 15 versus 15
or more, and less than 20 versus 20 or more. On analysis of
survival differences based on the number of involved LNs,
patients were categorized into groups of those with 0 versus
1 or more, less than 3 versus 3 or more, less than 4 versus 4
or more, and less than 5 versus 5 or more of involved LNs.
Survival curves were plotted using the Kaplan-Meier method.
Differences in survival among the groups were examined
using the log-rank test. A two-category comparison was
performed using the Pearson 2 test and the Student t test for
quantitative data. Multivariate analysis was performed using
the Cox proportional hazards model to examine any possible
association between the ratio of the total number of RLNs and
involved LNs and survival, with adjustment for the effects of
other potential prognostic factors, including age, sex, histol-
ogy, tumor factor, and type of surgery performed. All tests
were two sided, and p values of less than 0.05 were consid-
ered to represent statistically significant differences. Stat-
View version 5.0 software (SAS Institute Inc., Cary, NC) was
used for statistical analysis.
Ethical Considerations
The approval of the Institutional Review Board of
Tokyo Medical University was obtained, but as this was a
retrospective study the need to obtain written informed con-
sent from either the patients or their representatives was
waived, in accordance with the AMA Manual of Style (10th
edition).
TABLE 1. Patient Characteristics
Variable Category n (%)
Age (yr) Mean 65.0
Range 22–87
Sex Men 548 (59.0)
Women 380 (41.0)
Histopathology Adenocarcinoma 684 (73.7)
Squamous cell 182 (19.6)
Large cell 52 (5.6)
Other 10 (1.1)
Clinical stage I 768 (82.8)
II 84 (9.1)
III 76 (8.1)
Pathological stage I 677 (72.9)
II 121 (13.0)
III 130 (14.1)
Tumor location Right side 602 (64.9)
Upper/middle/lower 334/64/204
Left side 326 (35.1)
Upper/lower 190/136
Surgical procedure Lobectomy 870 (93.8)
Bilobectomy 42 (4.5)
Pneumonectomy 16 (1.7)
Total number of resected LNs Mean (range) 15.0 (1–49)
0–4 59 (6.4)
5–9 177 (19.1)
10–14 251 (27.0)
15–19 201 (21.6)
20 241 (25.9)
Total number of involved LNs
in positive cases
Mean (range) 4.2 (1–22)
0 724 (78.0)
1–3 122 (13.1)
4 82 (8.9)
LNs, lymph nodes.
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RESULTS
Survival and Number of RLNs
We investigated the prognostic impact of the number of
RLNs (mean number of RLNs  15). Patients were catego-
rized into four representative groups according to the total
number of RLNs: less than 5 versus 5 or more, less than 10
versus 10 or more, less than 15 versus 15 or more, and less
than 20 versus 20 or more (Figure 1). Table 2 presents each
p value, hazard ratio (HR), and 95% CI comparing each
subgroup categorized according to total number of RLNs.
The largest significant difference was found in the total
number of RLNs categorized between less than 10 and 10 or
more (p  0.0199, HR  1.795, 95% CI  1.098–2.912).
However, even 15 or more RLNs had no significant prognos-
tic impact on the survival of patients with NSCLC in the
present series. There was no sign of incremental improve-
ment in or impairment of survival after the resection and
evaluation of 15 or more LNs for curative resection of
NSCLC. There were no statistically significant differences in
survival according to the total number of RLNs in cases of
stage I NSCLC (Figure 2).
As shown in Table 3, the mean numbers of RLNs on
both the right and left sides were significantly higher in pN1
or pN2–3 cases than in pN0 cases (right side: p  0.0007,
p  0.0002, left side: p  0.0068, p  0.0162, respectively).
The mean number of RLNs in cases with right-sided tumors
was significantly higher than that in cases with left-sided
tumors.
Survival and Number of Involved LNs
We analyzed the number of involved LNs that could
provide the most appropriate indicator of OS in NSCLC.
Although the incidence of LN involvement was associated
with poor prognosis, the largest statistically significant in-
crease in OS was observed between zero to three and four or
more involved LNs (HR, 7.680; 95% CI, 5.051–11.655, p 
0.0001) (Figure 3). Although patients with no involved LNs
had a better outcome than those with 1 to 3 involved LNs,
there was no significant difference in survival between the
two groups (p 0.1831). Patients with four or more involved
LNs had a significantly worse outcome than those with one to
three involved LNs (p  0.0001). These results suggest that
four or more involved LNs would be the best benchmark of
OS in NSCLC (Figure 4).
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FIGURE 1. Survival curves accord-
ing to the number of resected LNs
at the time of complete resection
in patients with stages I to III non-
small cell lung cancer. A, LN, five
nodes as cutoff. B, LN, 10 nodes as
cutoff; a significant difference in
survival was observed. C, LN, 15
nodes as cutoff. D, LN, 20 nodes as
cutoff.
TABLE 2. Correlations between Overall Survival and Total
Number of Resected Lymph Nodes
Valuables p HR 95% CI
5 vs. 5 0.7464 1.135 0.528–2.440
6 vs. 6 0.5464 1.233 0.624–2.437
7 vs. 7 0.1611 1.591 0.831–3.047
8 vs. 8 0.744 1.725 0.948–3.140
9 vs. 9 0.0217 1.783 1.088–2.923
10 vs. 10 0.0199 1.795 1.098–2.912
11 vs. 11 0.0295 1.651 1.051–2.595
12 vs. 12 0.0473 1.521 1.005–2.302
13 vs. 13 0.0907 1.394 0.949–2.050
14 vs. 14 0.1137 1.354 0.930–1.973
15 vs. 15 0.0832 1.388 0.956–2.014
HR, hazard ratio; CI, confidence interval.
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Correlations between Number of RLNs,
Involved LNs and pN Status
Before analyzing the possibility of RLNs and involved
LNs as possible independent prognostic factors by multivar-
iate analysis, we examined whether RLNs, involved LNs and
pN status were confounding factors. The mean and range of
the total number of RLNs in our series were 15.0 and 1 to 49,
respectively. The mean number of RLNs was significantly
increased in pN1 or pN2–3 cases compared with pN0 cases
(p 0.0001 and p 0.0001, respectively), whereas the mean
and range of the total number of involved LNs in our
pN-positive series were 4.2 and 1 to 22, respectively. The
mean numbers of involved LNs in pN1 and pN2–3 cases were
2.15 and 6.56, respectively. The number of involved LNs was
significantly higher in pN2–3 cases than in pN1 cases (p 
0.0001). These results demonstrate that each of these prog-
nostic factors (i.e., the number of RLNs and involved LNs,
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FIGURE 2. Survival curves accord-
ing to the number of resected LNs
at the time of complete resection
in patients with stage I, non-small
cell lung cancer. A, LN, five nodes
as cutoff. B, LN, 10 nodes as cutoff.
C, LN, 15 nodes as cutoff. D, LN,
20 nodes as cutoff. No significant
difference in survival was observed
in any group.
TABLE 3. Mean Number of Resected Lymph Nodes on
Right or Left Side
Mean Number p
Right side lymph nodes,
n  602
Total 15.5
pN0 14.7
pN1 18.2 0 vs. 1: p  0.0007a
pN2–3 19.0 0 vs. 2–3: p  0.0002a;
1 vs. 2–3: p  0.7199
Left side lymph nodes,
n  326
Total 14.3
pN0 13.5
pN1 16.6 0 vs. 1: p  0.0068a
pN2–3 16.3 0 vs. 2–3: p  0.0162;
1 vs. 2–3: p  0.8985
Right vs. left p  0.0323a
a Statistical significance.
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FIGURE 3. Survival curves according to the number of in-
volved LNs at the time of complete resection in patients
with stages I to III, non-small cell lung cancer. A, LN, one
node as cutoff. B, LN, three nodes as cutoff. C, LN, four
nodes as cutoff. D, LN, five nodes as cutoff. Although the
incidence of lymph node involvement was statistically associ-
ated with poor prognosis, the largest statistically significant
increase in OS was seen between zero to three and 4 or
more involved LNs.
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and pN status) were confounding factors in our series. There-
fore, in the subsequent multivariate survival analysis, we used
the ratio between the number of involved and RLNs to reflect
both factors in the multivariate analysis similarly to a previ-
ously reported method.11
Multivariate Survival Analysis
We performed multivariate analysis to confirm the
prognostic impact of the total number of RLNs and involved
LNs in NSCLC, using the ratio between the number of
involved and RLNs, according to a previously observed
correlation.11 As shown in Table 4, RLNs strongly correlated
with poor prognosis on multivariate analysis after adjust-
ments for sex, age, histology, tumor factor, and surgical
procedure. We therefore concluded that RLN was a strong
independent prognostic factor for NSCLC (HR, 6.803; 95%
CI, 4.137–11.186, p 0.0001). Other independent prognostic
factors identified on multivariate analysis included sex (HR,
0.620; 95% CI 0.401–0.958, p  0.0313), age (HR, 1.598,
95% CI 1.090–2.341, p  0.0162), and T factor (HR, 0.392,
95% CI, 0.256–0.600, p  0.0001).
DISCUSSION
We set out to determine the number of LNs that should
be resected, and the number of involved LNs for the accurate
prediction of outcome in resectable cases of lung cancer.
Opinions still vary among surgeons as to whether to remove
all, some, or none of the mediastinal LNs at the time of
pulmonary resection for lung cancer, and practices vary
worldwide. In almost all surgical cooperative group trials in
North America, LN sampling is standard, whereas systematic
LN dissection is standard in Japan.
LN status is a major determinant of stage and survival
in patients with lung cancer. However, the role of mediastinal
lymphadenectomy in the staging and treatment of NSCLC
remains controversial. The present results indicate that pa-
tient survival after complete NSCLC resection is associated
with the number of LNs harvested during surgery. The largest
significant difference was observed in the total number of
RLNs categorized between less than 10 and 10 or more (p 
0.0199, HR  1.795, 95% CI  1.098–2.912). Patients with
10 or more RLNs had significantly worse outcomes than
those with less than 10 RLNs (Figure 1), contrary to the
findings of previous studies of stage I NSCLC cases.11–13 As
shown in Table 3, the mean number of RLNs on both the
right and left sides was significantly higher in pN1 or pN2–3
cases than in pN0 cases (right side: p  0.0007, p  0.0002;
left side: p  0.0068, p  0.0162, respectively), which may
be one reason why patients with NSCLC with 10 or more
RLNs had a worse outcome than those with less than 10
RLNs. According to the results of the American College of
Surgeons Oncology Group (ACOSOG) Z0030 study, a higher
N stage was also associated with increased LN removal (N0:
19.2 10.1; N1: 22.8 10.9; N2: 24.5 10.8; p 0.043).12
This is possibly because surgeons tend to harvest more LNs
in patients with LN-positive disease at the time of surgery, in
expectation of therapeutic benefit. However, even 15 or more
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FIGURE 4. Survival curves according to the number of in-
volved LNs at the time of complete resection in patients
with stages I to III, non-small cell lung cancer. Although pa-
tients with no involved LNs had a better prognosis than
those with one to three involved LNs, there was no signifi-
cant difference in survival between the two groups. Patients
with four or more involved LNs had a significantly worse
outcome than those with one to three involved LNs.
TABLE 4. Univariate and Multivariate Survival Analyses
Variable Category n
Univariate Analysis
p
Multivariate Analysis
HR 95% CI p
Sex Men 548 0.011a 0.620 0.401–0.958 0.0313a
Women 381
Age (yr) 70 690 0.0209a 1.598 1.090–2.341 0.0162a
70 338
Histopathology Non-adenocarcinoma 244 0.015a 0.790 0.518–1.203 0.2719
Adenocarcinoma 684
T factor T2–3 433 0.0001a 0.392 0.256–0.600 0.0001a
T1 495
Surgical procedure Lobectomy 912 0.0136a 2.521 0.768–8.280 0.1273
Pneumonectomy 16
RLNs 0.4 882 0.0001a 6.803 4.137–11.186 0.0001a
0.4 46
a Statistical significance.
RLNs, ratio between the number of involved and resected lymph nodes; CI, confidence interval; HR, hazard ratio.
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RLNs had no significant impact on OS in patients with
NSCLC in the present series, contrary to the results of a
previous large study.13 There appeared to be neither incre-
mental improvement nor impairment of survival after resect-
ing and evaluating 15 or more LNs with curative intent in
NSCLC in the current series. One possible explanation for
this is that the presence of approximately 10 dissected LNs
increases the staging accuracy.
There was no significant difference in survival accord-
ing to the total number of RLNs in stage I NSCLC in the
current series. Recent retrospective studies from cancer reg-
istries,14 nonrandomized trials,15 and other institutions,16–21
have indicated that the number of RLNs is associated with
better OS.16–19 Although LN removal may be therapeutic, the
therapeutic benefit is likely to be small for patients with stage
IA NSCLC, because all LNs in stage IA should be negative.
The other, less likely explanation, is that a more extensive LN
dissection such as systematic mediastinal LN dissection may
be therapeutic, at least in stage I NCSLC.
The present analysis shows that an increasing number
of RLNs during complete NSCLC resection is associated
with a statistically significant difference in survival, which
peaks at 10 to 14 LNs. Some studies have recommended that
the minimum requirements for accurate nodal staging must
include the removal of at least six LNs from hilar and
mediastinal stations.7,22,23 However, others have recom-
mended the examination of a minimum of 10 LNs and at least
three LN stations.14,19 Although we are reluctant to recom-
mend a definitive optimal number of LNs, the current data
support the conclusion that an evaluation of nodal status
should include at least 10 LNs.
Nodal involvement is the most important prognostic
factor in determining survival for many malignant tumors.
These factors are represented by the N category in the TNM
classification and are grouped according to the anatomical
location and/or number of LN involvement. In the most
recently published 7th edition of the TNM Classification of
Malignant Tumors (2009),24 the number of involved LNs is
included in the definition of pN factors in breast, stomach,
esophageal, and colorectal cancer, and pN status shows a
significant correlation with outcome. The nodal system in this
edition in lung cancer is still based on the anatomical location
of involved LNs. The Naruke map and the American Tho-
racic Society map have been combined into the International
Association for the Study of Lung Cancer map, and the
definition of the border between N1 and N2 has been
changed, because of its complexity and ambiguity. However,
this change is based on the anatomical location, not on the
biological issue. In the current study, we predicted patient
outcome after complete NSCLC resection according to the
number of involved and RLNs, as previous reports have
suggested.25,26 Recently, Asamura and coworkers27 have pro-
vocatively suggested that the number of metastatic LNs
provides more accurate pathologic nodal staging than the
current method of considering anatomical location of in-
volved nodes. The largest statistically significant increase in
OS was observed between zero to three and four or more
involved LNs (HR, 7.680; 95% CI, 5.051–11.655; p 
0.0001) (Figure 2). Therefore, the current data indicate that
four or more involved LNs serve as a good indicator of
outcome after complete NSCLC resection. Because it is
possible that the number of RLNs and involved LNs may
indicate the quality of surgery in the determination of accu-
rate staging and survival impact after complete NSCLC
resection, we used RLNs as a prognostic predictor on
multivariate analysis. In addition to T stage, RLNs had a
strong independent effect on survival in patients with
complete NSCLC resection in the present study. Indeed,
the 5-year survival ratio of patients with RLNs 4 is
similar to that of patients with pN2 disease in our series
(data not shown). Although the nodal classification accord-
ing to the number of involved LNs is simple and easy to be
incorporated in the next TNM classification, there are a
few limitations that are not helpful in deciding treatment
preoperatively because it is mainly based on pathological
assessment. However, this may change in the future with
the development of new imaging device.
Our data suggested that the number of involved LNs
expands pN category information and may provide additional
information for the pN category of the next TNM classifica-
tion. Further large-scale cohort studies, including global pro-
spective validation analyses and multi-institutional studies
are warranted.
CONCLUSION
We retrospectively evaluated the prognostic impact of
the number of RLNs and involved LNs on the survival of
patients with complete NSCLC resection. We found that 10
or more LNs harvested with complete LN dissection possibly
influenced survival after complete NSCLC resection. More-
over, the presence of four involved LNs seemed to be a good
indicator of outcome after complete NSCLC resection. The
number of involved LNs was a strong independent prognostic
factor in NSLC, and this may provide new information for the
N categorization of the next TNM classification.
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